Analyst Ratings For Dimension Therapeutics (NASDAQ:DMTX)
Today, Dimension Therapeutics (NASDAQ:DMTX) stock received an upgrade by Citigroup Inc. from Sell to Neutral.
There are 4 hold ratings, 1 buy rating on the stock.
The current consensus rating on Dimension Therapeutics (NASDAQ:DMTX) is Hold (Score: 2.20) with a consensus target price of $4.73 per share, a potential 19.87% downside.
Some recent analyst ratings include
- 10/3/2017-Citigroup Inc. Upgrade from a “Sell ” rating to a ” Neutral” rating.
- 8/30/2017-Canaccord Genuity was Downgraded by analysts at Canaccord Genuity from a “Buy ” rating to a ” Hold” rating. They now have a $3.41 price target on the stock, up previously from $12.00 .
- 8/14/2017-Chardan Capital Reiterated Rating of Hold.
- 2/2/2017-Jefferies Group LLC Reiterated Rating of Buy.
- 3/30/2016-Goldman Sachs Group, Inc. (The) was Downgraded by analysts at Goldman Sachs Group, Inc. (The) from a “Buy ” rating to a ” Neutral” rating. They now have a $10.00 price target on the stock.
- 12/3/2015-Wells Fargo & Company initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Dimension Therapeutics (NASDAQ:DMTX)
Dimension Therapeutics (NASDAQ:DMTX) has insider ownership of 2.18% and institutional ownership of 70.75%.
- On 6/7/2016 K. Reed Clark, SVP, sold 5,000 with an average share price of $10.00 per share and the total transaction amounting to $50,000.00. View SEC Filing
- On 10/27/2015 Rishi Gupta, Director, bought 200,000 with an average share price of $13.00 per share and the total transaction amounting to $2,600,000.00. View SEC Filing
Recent Trading Activity for Dimension Therapeutics (NASDAQ:DMTX)
Shares of Dimension Therapeutics closed the previous trading session at with shares trading hands.
